C-GNMMYap Therapeutics
AAV gene therapy, Hippo/YAP modulation, advanced biologics
repairinggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-GNMM
C-GNMMC-GNMMAAV gene therapy, Hippo/YAP modulation, advanced biologics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
--> News & Publications | Medley Therapeutics top of page About Us Technology Leadership News & Publications Contact First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle NorthStar Medical Radioisotopes and YAP Th
--> Technology | Medley Therapeutics top of page About Us Technology Leadership News & Publications Contact Technology Platforms Medley Therapeutic’s genetic medicine platform aims to activate the dormant regenerative potential inherent in our DNA, while the advanced biologics platform targets the progressive conditions such as solid tumor cancers and organ fibrosis. Genetic Medicine Platform Our proprietary genetic medicine platform based on IP licensed from Baylor College of Medicine and Texas Heart Institute represents a paradigm shift in therapeutic approach. Instead of merely tr
--> Technology | Medley Therapeutics top of page About Us Technology Leadership News & Publications Contact Technology Platforms Medley Therapeutic’s genetic medicine platform aims to activate the dormant regenerative potential inherent in our DNA, while the advanced biologics platform targets the progressive conditions such as solid tumor cancers and organ fibrosis. Genetic Medicine Platform Our proprietary genetic medicine platform based on IP licensed from Baylor College of Medicine and Texas Heart Institute represents a paradigm shift in therapeutic approach. Instead of merely tr
--> Home | Medley Therapeutics top of page About Us Technology Leadership News & Publications Contact Notes of hope for patients. Revolutionizing treatment through genetic medicine & advanced biologics. Our Mission Deliver transformative genetic medicines and advanced biologics to effectively treat large market chronic diseases. Links About Us Technology Leadership News & Publications Contact Contact 26051 Merit Circle, Suite 102 Laguna Hills, CA 92653 Houston office: 713.321.2725 Laguna Hills office: 949.348.1188 Social Media bottom of page
Contract catch-up: The latest cross-modality CDMO deals BioProcess International is part of the Informa Connect Division of Informa PLC Informa PLC | ABOUT US | INVESTOR RELATIONS | TALENT This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. BPI Events About Subscribe Contribute Stay Updated Stay Updated Upstream Related Topics Bioreactors Biochemicals/Raw Materials Cell Culture Media Expression Platforms Microbial Cell
List of rebranded biotech, pharma & medical device companies About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact 0 Rebranded/Renamed Biotech Companies 20 20 Gene Systems Renamed 20/20 BioLabs, Apr 2025 3-V Biosciences Renamed Sagimet Biosciences, Aug 2019 3DBio Therapeutics Renamed PrintBio 3DBiopsy Renamed Triopsy 480 Biomedical Renamed Lyra Therapeutics, Sep 2018 4s3 Bioscience Changed named to Valerion Therapeutics 2012 A&Z Pharmaceutical Effectively renamed Allegiant Health &nbs
Biotech - Startup and Tech News - Madison StartupsStartup and Tech News – Madison Startups Startup News General & Events Tech Biotech Goods & Services Madison Startups Monthly Digest Press Releases Startup Events Startup Database Startup Resources Contact Category Archives: Biotech Promega, EditCo Bio to Partner April 24, 2025 - Biotech - Tagged: Promega - no comments Promega has partnered with EditCo Bio, a leader in engineered cell solutions, offering high-quality, functionally validated CRISPR-edited cell lines, the company announced recently. “This agreement accelerates sci
First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle - Cardiac Vascular News Follow us twitter linkedin CardiacVascular Executive Search Submit News/Guest Posts Team CardiacVascular Executive Search Submit News/Guest Posts Team The Latest Cardiac and Vascular News Coronary Peripheral EP Neuro Radiology Regulatory Financial Interviews Coronary Peripheral EP Neuro Radiology Regulatory Financial Interviews Coronary/Structural Heart First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regener … in Canada June 22, 2026 Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026 June 18, 2026 Share this story Facebook Twitter LinkedIn Medley Therapeutics (formerly YAP Therapeutics) has dosed the first cohort (n=3) with YAP101 in the Phase 1 SALVADOR-HF trial at The Texas Heart Institute at Baylor College of Medicine in the Baylor St. Luke’s Medical Center (Houston). This is the first clinical investigation of a genetic me … d their best teams possible at the executive level. Prior to search, Ken had an award winning commercial career at Boston Scientific and Johnson & Johnson to include such prestigious awards as President's Club, Ring Club, and Grand Awards. [email protected] Leave a Comment Cancel Your email address will not be published. Required fields are marked * Message Name * Email Address * Website Save my name, email, and website in this browser for the next time I comment. Not … nnounces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II Study Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System Access Vascular and Medline Enter Multi-Year Agreement to Launch Cobranded Next-Generation Vascular Access Catheters Popular No commented posts yet Subscribe to Blog via Email Enter your email address to subscribe to this blog and receive n
NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developmen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products January 8, 2025 | 3 min read Twitter LinkedIn Facebook Email Print NorthStar to support the development of YAP Therapeutics' innovative radiolabeled pr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
NorthStar Medical Radioisotopes and YAP Therapeutics Enter Into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products – 1stOncology™: Cancer Intelligence Service 1stOncology™: Cancer Intelligence Service 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Skip to content 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers , signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you
NorthStar and YAP Therapeutics Partner to Develop Radiopharmaceutical Products - PharmaSource Toggle Side Panel News + Resources Downloads & Resources CDMO News CRO News Market Trends and Category Guides Biotech Profiles Podcast Directory Events CDMO Live ExM Leaders More options Sign in Sign up Search for: News + Resources Manufacturing News Podcast Downloads & Resources Biotech Profiles Directory Events Search for: Close search AI + Digital Maturity in Contract Manufacturing Exclusive Report External Manufacturing Leaders Boston Register CDMO Live Americas 2026 Early Bird Agenda Down
YAP Therapeutics Archives - Cardiac Vascular News Follow us twitter linkedin CardiacVascular Executive Search Submit News/Guest Posts Team CardiacVascular Executive Search Submit News/Guest Posts Team The Latest Cardiac and Vascular News Coronary Peripheral EP Neuro Radiology Regulatory Financial Interviews Coronary Peripheral EP Neuro Radiology Regulatory Financial Interviews Tag: YAP Therapeutics NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products Financial January 8, 2025 by Ken Dropiewski … nnounces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II Study Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System Access Vascular and Medline Enter Multi-Year Agreement to Launch Cobranded Next-Generation Vascular Access Catheters Popular No commented posts yet Subscribe to Blog via Email Enter your email address to subscribe to this blog and receive n
YAP Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Par … AP Therapeutics Patents YAP Therapeutics has filed 1 patent. View Patents Chart Application Date Grant Date Title Related Topics Status 6/29/2023 Gene therapy of hippo signaling improves heart function in a clinically relevant model Application Application Date 6/29/2023 Grant Date Title Gene therapy of hippo signaling improves heart function in a clinically relevant model Related Topics Status Application Learn more by requesting a demo Latest YAP Therapeutics News NorthStar
Fjord Ventures - Massinvestor Venture Capital and Private Equity Database Company Information VC Fjord Ventures https://www.fjordventures.com Office Locations: 26051 Merit Circle, Suite 102 Laguna Hills, CA 92653 Phone: 949-348-1188 Fax: 949-348-1866 Stages: Early Industries: Business Services Consumer Products & Services Financial Services Life Sciences & Healthcare Medical Device Description: Fjord Ventures, LLC was founded in 2005 and is committed to providing strategic vision and operating experience to emerging life science co … lly progress through this evaluation phase prior to potential investment by the Fund. Fjord also engages in buyouts of assets or companies with promising technologies, but with failed execution or lack of investor support. Fjord targets company exits earlier than traditional venture capital. Fjord companies typically exit prior to initiating commercialization activities that are performed more efficiently by the large corporate buyer. The firm's portfolio is managed by Fjord' … h has over 50 years of combined operating experience. Funds: Fund Name Amount Date Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Southern California Database subscription . Investment Firm Key VC = Venture Capital PE = Private Equity A = Angel I = Incubator & … Debt FI = Family Investment Office FOF = Fund of Funds ED = Economic Development Office TT = Technology Transfer Office CVC = Corporate Venture Capital SEC = Secondary Purchaser HF = Hedge Fund/Mutual Fund COMPANY STAGE REVENUE Venture Capital Seed Stage (includes "pre-s
S-1 1 d203375ds1.htm S-1 S-1 Table of Contents As filed with the U.S. Securities and Exchange Commission on October 8, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sonendo, Inc. (Exact name of registrant as specified in its charter) Delaware 3843 20-5041718 (State or other jurisdiction of incorpo … adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take 8 Table of Contents advantage of this extended transition period and, as a result, our operating results and financial statements may not be comparable to the operating results and financial statements of companies who have adopted the new or revised accounting standards. Section 107 of the JOBS Act provides that we can elect to opt o … d our commercial organization and increase our sales and marketing programs, to fund our research and development activities and clinical initiatives to support adoption of our products, and the remainder for working capital and general corporate purposes. See “Use of Proceeds.” Dividend policy We do not expect to pay any dividends on our common stock for the foreseeable future. See “Dividend Policy.” Proposed New York Stock Exchange symbol & … n stock that will become available for future issuance under our 2021 Incentive Award Plan, or the 2021 Plan, which will become effective in connection with the completion of this offering, as well as any shares that become issuable pursuant to the provisions of the 2021 Plan that automatically increase the share reserve under the 2021 Plan; • shares of ou … we expect that our existing cash and cash equivalents will not be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of this prospectus. This estimate is based on our current assumptions, including assumptions relating to our ability to manage our spending, that might prove to be wr
10-K FY false 0001676725 P3Y 2020 2021 http://www.ideayabio.com/20241231#PresidentAndCEOMember 0001676725 idya:PolymeraseThetaProgramMember srt:MaximumMember 2020-06-30 0001676725 us-gaap:CommercialPaperMember 2023-12-31 0001676725 us-gaap:LeaseAgreementsMember idya:SouthSanFranciscoCaliforniaMember 2024-01-01 2024-12-31 0001676725 us-gaap:LeaseAgreementsMember idya:SouthSanFranciscoCaliforniaMember 2023-06-30 0001676725 stpr:CA 2024-01-01 2024-12-31 0001676725 idya:JefferiesLLCMember us-gaap:CommonStockMember idya:AtTheMarketOfferingMember idya:JuneTwoThousandTwentyThreeSalesAgreementMember 2 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … es, exemption from certain user fees and, subject to FDA approval of a New Drug Application, or NDA, for darovasertib in UM, eligibility for seven years of statutory marketing exclusivity during which the FDA is prohibited from approving a subsequent same drug for the same rare disease or condition except in limited circumstances, such as a subsequent drug that demonstrates clinical superiority. As an FDA-designated Orphan Drug, darovasertib may also be excluded from certain … actions, such as meetings and written communications, potential eligibility for rolling review of a future NDA and potential accelerated approval and priority review of an NDA. Darovasertib – Phase 2 Trials in Neoadjuvant and Adjuvant Therapy in Uveal Melanoma (UM) We are clinically evaluating the potential for darovasertib as neoadjuvant or adjuvant therapy, or both, also referred to as (neo)adjuvant therapy, in primary, non-metastatic UM patients. We previously report … nteractions (e.g., meetings, written communications), potential eligibility for rolling review, accelerated approval, and priority review of a future NDA.   In March 2024, we entered into the Merck CTCSA with Merck (known as MSD outside of the United States and Canada). We are evaluating the combination of IDE161 and Merck’s anti-PD-1
Medley Therapeutics completes Phase 1 trial of YAP101 for heart failure | PackGene Biotech, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … cebook X To view or add a comment, sign in Waimun Kong 7mo Report this post The application of CD19/CD20/BAFF CAR-T, in vivo CART and monoclonal antibodies is expanding beyond oncology into complex autoimmune conditions such as SLE. Recent clinical data indicates that controlled B-cell depletion followed by immune reconstitution may offer durable remission in refractory SLE, reducing reliance on long-term immunosuppression. This demonstrates the broader therapeutic potential … ch will gain expedited communication with the FDA, eligibility for priority and rolling review, and a clearer path to accelerated development. • The move reflects a broader trend: next-gen cell therapies are not just targeting more common cancers but also tackling hard-to-treat hematologic malignancies with novel antigens (CD5) and streamlined manufacturing. Looking ahead: March Biosciences plans to engage with the FDA on the next steps of development and review. Interim data
YAP101 / Medley Therapeutics YAP101 / Medley Therapeutics - LARVOL DELTA Home Next Prev 1 to 2 Of 2 Go to page 1 April 10, 2025 Gene Therapy Targeting the Hippo Pathway for In Vivo Cardiac Regeneration in Ischemic Heart Failure (ASGCT 2025) - "By coordinating in vivo cardiomyocyte cell division, vascular recruitment, and fibrosis reduction, YAP101 activates cardiac regeneration, leading to improved cardiac function and offering a potential breakthrough treatment for ischemic heart failure. Disease Focus of Abstract:Cardiovascular/Heart Disease" Gene therapy • Preclinical • Cardiovasc
YAP101 Passes First Safety Milestone in Clinical Trial - Martin Heart Lab 0 Skip to Content Research Team Overview Director Collaborating Faculty Assistant Directors/Faculty Postdoctoral Fellows Graduate Students Martin Lab Alumni News Publications Medley Therapeutics Open Menu Close Menu Research Team Overview Director Collaborating Faculty Assistant Directors/Faculty Postdoctoral Fellows Graduate Students Martin Lab Alumni News Publications Medley Therapeutics Open Menu Close Menu Research Folder: Team Back Overview Director Collaborating Faculty Assistant Directors/Faculty Postdoctoral Fell
Medley Doses First Cohort in AAV Gene Therapy Trial for Heart Regeneration | PackGene Biotech Discovery and Preclinical AAV Packaging Services AAV Production Services AAV Packaging – Research Grade AAV Packaging – NHP Grade Express Gene-to-AAV Service Off the Shelf AAV Products AAV Testing Services AAV Testing Services Mass Photometry AAV Genome Titer by ddPCR AAV Empty/Full Capsid Ratio Test by AUC AAV Genome Integrity by CE AAV Genome Sequencing by Nanopore AAV Capsid Services Capsid Engineering AAV Capsid Discovery Kits AAV Capsid & Gene Library Services Lentivirus Services Express Gen … omprehensive release testing. Rapid timeline to GMP AAV production and clinical application, backed by a strong record of successful delivery. Proven track record of supporting over 40 IIT (Investigator-Initiated Clinical Trial) programs. AAV Packaging – Research Grade Delivery in as little as 12 days from miniprep to purified AAV virus. High purity, low endotoxin levels and minimal empty capsids for reliable performance. Access to 70+ serotypes and expert support, backed by
Medley Therapeutics, Inc. (Medley Therapeutics, Inc.) - 药物管线_专利_临床试验_投融营收_最新药物:YAP-101，MED103，MED102 产品 数据 资源 版本对比 预约演示 免费注册 更新于：2026-06-21 Medley Therapeutics, Inc. 控股公司 | California, United States | < 10 | www.yaptx.com 控股公司 | California, United States | < 10 | www.yaptx.com 更新于：2026-06-21 概览 管线布局 药物交易 转化医学 营收 科研基金(NIH) 投资 融资 概览 标签 心血管疾病 肿瘤 其他疾病 基因疗法 生物药 放射与诊断药物 疾病领域得分 一眼洞穿机构专注的疾病领域 暂无数据 技术平台 公司药物应用最多的技术 暂无数据 靶点 公司最常开发的靶点 暂无数据 疾病领域 数量 肿瘤 2 排名前五的药物类型 数量 基因疗法 4 生物药 2 放射与诊断药物 1 ADC 1 关联 8 项与 Medley Therapeutics, Inc. 相关的药物 YAP-101 靶点 - 作用机制 - 在研机构 Medley Therapeutics, Inc. 原研机构 Medley The
NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products | NorthStar Medical Radioisotopes, LLC NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products | NorthStar Medical Radioisotopes, LLC Close Radiopharmaceutical Therapy Overview The Science Why NorthStar Actinium-225 Copper-67 Scientific Advisors CDMO/CMO Development Overview Manufacturing Radiopharma Development Pipeline Company Overview Leader
Medley Therapeutics — Whiteford Research Biobase Company DB ← Company DB Company information is AI generated, and may be inaccurate. Medley Therapeutics Overview Medley Therapeutics, formerly YAP Therapeutics, is a privately held biotechnology company developing regenerative genetic medicines and advanced biologics for chronic and life-threatening diseases. The company was listed as a Houston, Texas participant at the 2025 Texas Life Science Forum, which described its portfolio as genetic medicines for endogenous organ repair plus advanced biologics for cancer and fibrotic disease. [1] Medley'
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Severe COVID-19 Patients: Discharged from Hospital, but Not Fully Recovered - DongA Science Korean Korean About Us This content was translated by an AI-powered translation tool. It may contain inaccuracies due to the limitations of machine translation. Copyright © DongA Science. All rights reserved. Article Summary AI highlights the key points. Severe COVID-19 Patients: Discharged from Hospital, but Not Fully Recovered ·연합뉴스 2020.11.13 15:52 KST Share Font - Font + Print 'Within 2 Months' 7% Died, 15% Readmitted, 39% Unable to Resume Normal Activities, a U of Michigan Study of 1,250 … US and China [Science Bulletin] 16 Engineers Win 2026 First-Half Korea Engineer Award Seoul National University study finds 33% of tongue-side teeth miss brushing ECMWF study finds 1 billion more people face extreme heat stress at night Lieber Institute team identifies 641 new schizophrenia genes through long-range genetic networks KRICT boosts CAR-T and CAR-NK cancer gene expression by up to 25% with new SRV2 vector Algae-Based Microrobots Boost Bladder Cancer Drug Penetrati
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
အခြေအမြစ်မရှိသော နှလုံးသွေးကြောဆိုင်ရာ မျိုးဗီဇကုထုံးသည် နှလုံးရောဂါဝေဒနာရှင်များအတွက် သိသိသာသာ ပြောင်းလဲနိုင်သော အလားအလာ | တက္ကဆက်နှလုံးဌာန® ","library":"fa-solid"},"layout":"horizontal","toggle":"burger"}" data-widget_type="nav-menu.default"> နှလုံးသွေးကြောကျန်းမာရေးစောင့်ရှောက်မှု နှလုံးကနျြးမာရေး သင်၏နံပါတ်များကိုသိပါ။ နှလုံးသတင်းအချက်အလက်စင်တာ အမေးအဖြေများ ဗီဒီယိုအချက်အလက် အမျိုးသမီးများ နှလုံးကျန်းမာရေး Straight Talk အမျိုးသမီးများ နှလုံးကျန်းမာရေး Cardiothoracic ခွဲစိတ်ကုသ နှလုံးရောဂါနှင့် ကာကွယ်ရေး စောင့်ရှောက်မှု Cardiom
NorthStar, YAP Therapeutics Partner to Develop & Manufacture Radiopharmaceuticals | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscri
Gene Therapy for Heart Failure | The Texas Heart Institute® Cardiovascular Healthcare Heart Health Know Your Numbers Heart Information Center FAQs Video Information Women’s Heart Health Straight Talk Women’s Heart Health Cardiothoracic Surgery Cardiology & Preventive Care Cardiometabolic Syndrome Heart Transplantation Comprehensive Vascular Care Center for Cardiovascular Care Cardiovascular Research Office of Research Administration Labs & Centers Cardiomyocyte Renewal Laboratory Cardiovascular Pathology Electrophysiology Clinical Research & Innovations Innovative Device & … D, PhD , THI’s Medical Director and a co-investigator. He added, “The practical application of YAP101 gene therapy is significant, and it has the potential to become a paradigm-changing treatment for heart failure.” YAP Therapeutics is a company co-founded by Dr. Martin with the late James T. Willerson, MD , former President of the THI, and Olav Bergheim, Founder and Managing Director of the life science venture accelerator Fjord Ventures, to develop and commercialize medicin
First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactur … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle November 11, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Medley Therapeutics (formerly YAP Therapeutics) has dosed the first cohort (n=3) with YAP101 in th … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Groundbreaking ການປິ່ນປົວດ້ວຍ Gene Cardiovascular ມີທ່າແຮງໃນການປ່ຽນແປງຢ່າງຫຼວງຫຼາຍສໍາລັບຄົນເຈັບຫົວໃຈລົ້ມເຫຼວ | ສະຖາບັນຫົວໃຈເທັກຊັດ® ","library":"fa-solid"},"layout":"horizontal","toggle":"burger"}" data-widget_type="nav-menu.default"> ການດູແລສຸຂະພາບ cardiovascular ສຸຂະພາບຫົວໃຈ ຮູ້ຕົວເລກຂອງເຈົ້າ ສູນຂໍ້ມູນຂ່າວສານຫົວໃຈ ຄໍາຖາມ ຂໍ້ມູນວິດີໂອ ສຸຂະພາບຫົວໃຈຂອງແມ່ຍິງ ເວົ້າກົງສຸຂະພາບຫົວໃຈຂອງແມ່ຍິງ ການຜ່າຕັດ Cardiothoracic ການປິ່ນປົວພະຍາດຫົວໃຈ ແລະການປ້ອງກັນ ໂຣກ cardiometabolic ການປ່ຽນຫົວໃຈ ການດູແລ vascular ທີ່ສົມບູນແບບ ສູນການດູແລຫົວໃຈ ການຄົ
Gene Therapy for Regenerating Heart Cells May Prevent Lethal Arrhythmias After Heart Attack | The Texas Heart Institute® Cardiovascular Healthcare Heart Health Know Your Numbers Heart Information Center FAQs Video Information Women’s Heart Health Straight Talk Women’s Heart Health Cardiothoracic Surgery Cardiology & Preventive Care Cardiometabolic Syndrome Heart Transplantation Comprehensive Vascular Care Center for Cardiovascular Care Cardiovascular Research Office of Research Administration Labs & Centers Cardiomyocyte Renewal Laboratory Cardiovascular Pathology Electrophysio
Dr. James Martin – Director of the Cardiomyocyte Renewal Lab at Texas Heart Institute – Elected to the 2021 Class of the National Academy of Inventors | The Texas Heart Institute® Cardiovascular Healthcare Heart Health Know Your Numbers Heart Information Center FAQs Video Information Women’s Heart Health Straight Talk Women’s Heart Health Cardiothoracic Surgery Cardiology & Preventive Care Cardiometabolic Syndrome Heart Transplantation Comprehensive Vascular Care Center for Cardiovascular Care Cardiovascular Research Office of Research Administration Labs & Centers Cardiomyocyt … rt failure. He holds 9 U.S. patents and applications, including one provisional application, all of which have been licensed to Yap Therapeutics, a company he co-founded. His research has been and is currently supported by multiple federal granting agencies, including multiple NIH NHLBI R01 and DOD grants. As Director of Texas Heart Institute’s Cardiomyocyte Renewal Lab, Dr. Martin leads a department that focuses on understanding how genetic pathways are connected to a … rt some of the most elite innovators on the horizon. With the NAI Senior Member award distinction, we are recognizing innovators who are rising stars in their fields and the innovative ecosystems that support their work,” said Paul R. Sanberg, NAI President. “This new class is joining a prolific group of academic visionaries already defining tomorrow.” Following a nomination for NAI Senior Member, individuals undergo a rigorous selection process by the NAI Advisory Com … Senior Members are elected biannually, and nominations are accepted on a rolling basis. Nominations are currently being accepted for the next Senior Member class. A full list of NAI Senior Members is available on the NAI website . ### ABOUT TEXAS HEART INSTITUTE (THI) The Texas Heart Institute, founded by world-renowned cardiovascular surgeon Dr. Denton A. Cooley in 1962, is a nonprofit organization dedicated to reducing the devastating toll of cardiovascular di
First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle | The Texas Heart Institute at Baylor College of Medicine LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your s
The Texas Heart Institute at Baylor College of Medicine Leads First-in-Human Gene Therapy Trial to Regenerate Damaged Heart Tissue | The Texas Heart Institute® Cardiovascular Healthcare Heart Health Know Your Numbers Heart Information Center FAQs Video Information Women’s Heart Health Straight Talk Women’s Heart Health Cardiothoracic Surgery Cardiology & Preventive Care Cardiometabolic Syndrome Heart Transplantation Comprehensive Vascular Care Center for Cardiovascular Care Cardiovascular Research Office of Research Administration Labs & Centers Cardiomyocyte Renewal Laboratory
Medley Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 23 Jun 2026 Medley Therapeutics, Inc. Holding Company | California, United States | < 10 | www.yaptx.com Holding Company | California, United States | < 10 | www.yaptx.com Last update 23 Jun 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Cardiovascular Diseases Neoplasms Other Diseases Gene therapy Biological products Radiopharmaceuticals and diagnostic agent Disease doma … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Medley Therapeutics launches first human gene therapy trial for heart failure regeneration - DongA Science Korean Korean About Us This content was translated by an AI-powered translation tool. It may contain inaccuracies due to the limitations of machine translation. Copyright © DongA Science. All rights reserved. Article Summary AI highlights the key points. Medley Therapeutics launches first human gene therapy trial for heart failure regeneration Seyoung Moon 2026.05.29 17:03 KST Share Font - Font + Print Nature reports SAV1-targeting cardiac gene therapy entering clinical stage amid rising … iss brushing [Science Bulletin] 16 Engineers Win 2026 First-Half Korea Engineer Award Lieber Institute team identifies 641 new schizophrenia genes through long-range genetic networks KRICT boosts CAR-T and CAR-NK cancer gene expression by up to 25% with new SRV2 vector Algae-Based Microrobots Boost Bladder Cancer Drug Penetration Tenfold NASA Uses JWST to Trace Interstellar Comet 3I/ATLAS to 12-Billion-Year-Old Planetary System Article Summary AI highlights the key points. A
Services - Martin Heart Lab 0 Skip to Content Research Team Overview Director Collaborating Faculty Assistant Directors/Faculty Postdoctoral Fellows Graduate Students Martin Lab Alumni News Publications Medley Therapeutics Open Menu Close Menu Research Team Overview Director Collaborating Faculty Assistant Directors/Faculty Postdoctoral Fellows Graduate Students Martin Lab Alumni News Publications Medley Therapeutics Open Menu Close Menu Research Folder: Team Back Overview Director Collaborating Faculty Assistant Directors/Faculty Postdoctoral Fellows Graduate Students Martin Lab Alumni News P
%PDF-1.7 %���� 16 0 obj > endobj xref 16 35 0000000016 00000 n 0000001322 00000 n 0000001466 00000 n 0000002759 00000 n 0000003141 00000 n 0000003392 00000 n 0000003506 00000 n 0000003832 00000 n 0000003867 00000 n 0000003980 00000 n 0000004677 00000 n 0000004994 00000 n 0000005538 00000 n 0000005649 00000 n 0000006027 00000 n 0000006353 00000 n 0000006896 00000 n 0000006988 00000 n 0000007606 00000 n 0000008085 00000 n 0000008690 00000 n 0000008787 00000 n 0000009284 00000 n 0000010103 00000 n 0000011121 00000 n 0000012206 00000 n 0000013327 00000 n 0000014455 00000 n 0000015486 00000 n 00000 … 730975fb21f xmp.did:66698a4c-6870-40d0-9790-bc36688fcdd4 default converted from application/x-indesign to application/pdf Adobe InDesign 20.0 (Macintosh) / 2024-11-01T10:44:44-05:00 application/pdf Adobe PDF Library 17.0 False endstream endobj 15 0 obj > endobj xref 0 16 0000000000 65535 f 0000033428 00000 n 0000034669 00000 n 0000039921 00000 n 0000041085 00000 n 0000045731 00000 n 0000046243 00000 n 0000046289 00000 n 0000046331 00000 n 0000048182 00000 n 0000049765 00000 n
YAP1 - Drugs, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 YAP1 Last update 08 May 2025 Basic Info Synonyms Protein yorkie homolog, Transcriptional coactivator YAP1, YAP + [6] Introduction Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signaling pathway, crucial for organ size control and tumor suppression by restricting proliferation and promoting apoptosis (PubMed: 17974916 , PubMed: 18280240 , PubMed: 18579750 , PubMed: 21364637 , PubMed: 304470 … er lives. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention,
%PDF-1.7 %���� 402 0 obj > endobj xref 402 48 0000000016 00000 n 0000002771 00000 n 0000002916 00000 n 0000002952 00000 n 0000004521 00000 n 0000004965 00000 n 0000005002 00000 n 0000005116 00000 n 0000005228 00000 n 0000005328 00000 n 0000005766 00000 n 0000006262 00000 n 0000006390 00000 n 0000007771 00000 n 0000008959 00000 n 0000010128 00000 n 0000011269 00000 n 0000012398 00000 n 0000013576 00000 n 0000014121 00000 n 0000014439 00000 n 0000014728 00000 n 0000015311 00000 n 0000015840 00000 n 0000017063 00000 n 0000017397 00000 n 0000017804 00000 n 0000018158 00000 n 0000019527 00000 n 000 … 50.000000 0.000000 25% Yellow CMYK PROCESS 0.000000 0.000000 25.000000 0.000000 application/postscript James Philpot Adobe Illustrator Artwork xmp.did:456e94a5-9060-0f45-9f30-6ad4335ee5c0 xmp.iid:456e94a5-9060-0f45-9f30-6ad4335ee5c0 xmp.did:456e94a5-9060-0f45-9f30-6ad4335ee5c0 converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application … 2014-09-30T12:59:07-05:00 Adobe Illustrator CC 2014 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator endstream endobj 443 0 obj > endobj 444 0 obj > endobj 445 0 obj >stream Adobe Illustrator 24.2 (Windows) 2020-07-13T10:24:20-05:00 2020-07-13T10:24:21-05:00 2020-07-13T10:24:21-05:00 1 Fals … 21933 Pixels Cyan Magenta Yellow Black Default Swatch Group 0 Adobe Illustrator application/postscript Symbol of Excellence James Philpot default xmp.did:9690f1dc-82c8-3e47-8daa-f957313faf16 xmp.iid:9690f1dc-82c8-3e47-8daa-f957313faf16 uuid:17e39aa8-0567-4f8d-9dcf-52d9bf3cc552 xmp.iid:887445aa-1295-b741-be37-2efd221372a8 xmp.did:887445aa-1295-b741-be37-2efd221372a8 uuid:17e39aa8-0567-4f8d-9dcf-52d9bf3cc552 default saved xmp.iid:0c0fb1c6-0e31-234f-9c99-13885473d798 2020-05-06T … f16 2020-07-13T10:24:21-05:00 Adobe Illustrator 24.2 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator Adobe PDF library 15.00 endstream endobj 446 0 obj > endobj 447 0 obj >/ExtGState >/Properties >>>/Subtype/Form>>stream H�\T�n1��W���Z\�� (�H ��!,A$��W��AB#͌ݵ������������??~^���R��� m ����`�Fep �⬓�0�J
News | NorthStar Medical Radioisotopes, LLC Close Radiopharmaceutical Therapy Overview The Science Why NorthStar Actinium-225 Copper-67 Scientific Advisors CDMO/CMO Development Overview Manufacturing Radiopharma Development Pipeline Company Overview Leadership News Facilities Library Contact Us Careers Search --> Search Radiopharmaceutical Therapy Overview The Science Why NorthStar Actinium-225 Copper-67 Scientific Advisors CDMO/CMO Development Overview Manufacturing Radiopharma Development Pipeline Company Overview Leadership News Facilities Library Contact Us Careers Search Company NEWS, PRE … dical radioisotope Mo-99 production in U.S. – − First and only commercial-scale application of innovative cMo-98 production technology – BELOIT, Wis., January 6, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radiopharmaceuticals used for medical imaging and […] Read more » December 10, 2020 Press Releases MONOPAR AND NORTHSTAR ANNOUNCE SELECTION OF uPRIT CANDIDATE FOR POTENTIAL TREATMENT … rld Council on Isotopes Honors NorthStar Medical Radioisotopes with President’s Award – Award Recognizes Outstanding Contributions to Isotopes and Their Uses to Benefit Mankind – BELOIT, Wis., April 14, 2020 — NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it has received the President’s Award from the World Council on Isotopes (WCI). The […] R … U.S. Producer of Medical Radioisotope Molybdenum-99 in Nearly 30 Years – Award for Outstanding Achievement presented at 2018 Molybdenum-99 Topical Meeting – Beloit, Wis., October 1, 2018 – NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it received an Award for Outstanding Achievement from the U.S. Department of Energy’s National Nuclear Security […] … Press Releases NorthStar Medical Technologies Receives Follow-on Award from National Nuclear Security Administration BELOIT, Wis. – NorthStar Medical Technologies LLC, parent company of NorthStar Medical Radioisotopes LLC, has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administ
SCGE Platform - Gene Therapy Clinical Trials × 👋 Hi there! I'm your AI assistant. Ask me anything about clinical trials, FDA documents! Contact SCGE Your email Message Send SCGE Consortium Home About SCGE TCDC Contact Us License Home Initiatives Therapeutic Leads Multiple Disease Platforms Platform Clinical Programs Regulatory Documents Gene Therapy Trial Browser All Trials Active Trials Recruiting Completed Trials Phase I Phase II Phase III IND Templates Phase 2 Publications Clinical Trials - Gene Therapy Trial Browser The Gene Therapy Trial Browser represents a unique pu … ngestive Heart Failure Hammond, H. Kirk, M.D. Completed Company is preparing to submit a plan to the FDA for the Phase 2b/3 study 216 more update(s) recently — View All All Recent Updates (221) × NCT06833983 Show Changes 2026-06-17 Eligibility criteria null 18 years old at the time of signing informed consent, And ≤65 years old: 3. participants with confirmed hemophilia a in their pre-admission history and based on clinical laboratory examination ; 4. subjects had used … ngestive Heart Failure Hammond, H. Kirk, M.D. Completed Company is preparing to submit a plan to the FDA for the Phase 2b/3 study NCT06765980 Show Changes 2026-06-17 Last update post date 2025-12-09 2026-04-30 curator Number of locations 2 3 curator Locations New zealand, Canada New zealand, Canada, Israel curator Eligibility criteria null Inclusion criteria: * participant must be between... api Record status Draft Active curator Preclinical publications LinkName:(Abstract #9 … points at least 4 weeks apart note: additional inclusion/exclusion criteria may apply, Per protocol">Key inclusion criteria: * documented gsdia with c... api Recent updates BLA Submission completed 12/30/25 BLA Submission completed 12/30/25, PDUFA Action Da... curator Fda designation Fast Track, Orphan Drug Designation, Rare Pediatri... Fast Track, Orphan Drug Designation, Priority Revi... curator Clinical publications null LinkName:Trial Interviews to Explore Glycogen Stor.. … eted Product was acquired by uniQure, uniQure did not renew their EMA marketing application when it expired 10/25/17, and Glybera is no longer commercially available NCT05541627 Show Changes 2026-06-17 Editor type none curator Therapy route In vivo curator Last update post date 2025-09-18 2026-05-14 curator Sponsor Brainvectis, A subsidiary of as
14th Annual Texas Life Science Forum Companies | Texas Life Science Forum Skip to main content BioHouston Rice Alliance Register Search Close Register Investors Sponsors Agenda Speakers Participating Companies Search Search Close Open Menu Close Register Investors Sponsors Agenda Speakers Participating Companies BioHouston Rice Alliance Register Enter a Search Term Search 14th Annual Texas Life Science Forum Companies Call for Ventures Now Open Join a group of nearly 600 innovative life science ventures that have presented at the premier Life Science Conference in Texas, co-hosted by Rice Alli … nting companies have raised $9.5B in funding with 69 exits. Call For Ventures - Apply Here CHECK OUT DETAILS ON THE 2024 COMPANIES Congratulations to the Most Promising Companies and People's Choice winners from the 13th Annual Texas Life Science Forum! 10 Most Promising: March Biosciences ImmunoGenesis Taurus Vascular Foxo Technology Voythos Loop Robots Case45 OmniNano Pharmaceuticals Mongoose Bio Rua Diagnostics People's Choice: Cytecom Michael E. DeBakey … nostics People's Choice: Cytecom Michael E. DeBakey Memorial Life Science Award, presented by BioHouston: Autoimmunity Biosolutions took home the Image Image 2024 Participating Companies 4M Therapeutics Aikynetix Anvil Diagnostics Autoimmunity BioSolutions Avesta76 Therapeutics AyuVis Research Barricade Therapeutics Case45 CorInnova Cx Precision Medicine Cytecom Diakonos Oncology Direct Biologics Eisana Health Exopert Cooperation Flat Medical Foxo Technolog
Raven.config('https://[email protected]/147999').install(); InnovationMap X Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation Awards Promoted Advertise Subscribe INNOVATIONMAP EMAILS ARE AWESOME Sign up now About Us Advertise Submit a Story Terms of Use Privacy Policy Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation Awards Promoted Advertise Subscribe 6 Houston health tech startups making major advancements … sectors. Six forward-thinking businesses have been named finalists for the 2025 award. They range from an end-of-life care company to others developing devices and systems for heart monitoring, sleep apnea, hearing loss and more. Read more about these businesses, their innovative founders, and how they're shaping the future of health care below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs , when the winner will be unveiled at our live awards … ous illnesses last year. Koda Health was founded out of the TMC's Biodesign Fellowship in 2020 by CEO Tatiana Fofanova, chief medical officer Dr. Desh Mohan, and chief technology officer Katelin Cherry. The company raised a $7 million series A earlier this year, and also announced major partnerships and integrations with Epic, Guidehealth, Medical Home Network, Privia Health and others. NanoEar NanoEar has miniaturized hearing aid technology so that it can be implanted ac … esses category, presented by Houston Powder Coaters. The finalists for the 2025 award , selected by our esteemed panel of judges, range from a company developing natural carbon-free fuel to another launching at-home sleep apnea technology. Read more about these innovative startups and the visionary female founders behind them below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs , when the winner will be unveiled at our live awards ceremony. Ticket … , including a seed round of funding that will support the growth of their team, fund early testing, and fuel Baritone's path toward FDA clearance. "2025 is going to be a big year for Bairitone, especially around solidifying our regulatory plan. The device we're making is really low risk — we're not putting anything into the body,
S-1/A 1 d203375ds1a.htm S-1/A S-1/A Table of Contents As filed with the U.S. Securities and Exchange Commission on October 25, 2021. Registration No. 333-260136 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sonendo, Inc. (Exact name of registrant as specified in its charter) Delaware 3843 20-5041718 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Cla … adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take 8 Table of Contents advantage of this extended transition period and, as a result, our operating results and financial statements may not be comparable to the operating results and financial statements of companies who have adopted the new or revised accounting standards. Section 107 of the JOBS Act provides that we can elect to opt o … d our commercial organization and increase our sales and marketing programs, to fund our research and development activities and clinical initiatives to support adoption of our products, and the remainder for working capital and general corporate purposes. See “Use of Proceeds.” Dividend policy We do not expect to pay any dividends on our common stock for the foreseeable future. See “Dividend Policy.” Proposed New York Stock Exchange symbol & … n stock that will become available for future issuance under our 2021 Incentive Award Plan, or the 2021 Plan, which will become effective in connection with the completion of this offering, as well as any shares that become issuable pursuant to the provisions of the 2021 Plan that automatically increase the share reserve under the 2021 Plan; • 525,600 shares of our common stock that will become available for future issuance under our 2021 Employee St … we expect that our existing cash and cash equivalents will not be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of this prospectus. This estimate is based on our current assumptions, including assumptions relating to our ability to manage our spending, that might prove to be wr
2024 Interstitial Lung Disease Symposium: Understanding Genetic Contributors to ILD - Stanford Center for Continuing Medical Education - Continuing Education (CE) <br>Led by the Stanford Division of Pulmonary, Allergy, and Critical Care, this CME symposium seeks to fulfill the need of practicing pulmonologists, primary care physicians, advanced-practice providers, and allied health care practitioners to incorporate knowledge of familial pulmonary fibrosis (FPF) into their comprehensive treatment plan for patients with interstitial lung disease.&nbsp;<br><br>A team of multidiscipli … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … Stanford Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This live activity is designated for 5.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Additional Information Cancellation Policy Cancellations received in writing no less than 20 days before the course will be refunded, less a 2 … onary & Critical Care Medicine, Stanford University Co-Course Director, Faculty Grant or research support-Boehringer Ingelheim Vetmedica GmbH Joshua James Mooney, MD Associate Medical Director for Lung and Heart Lung Transplantation Clinical Assistant Professor, Medicine- Pulmonary & Critical Care Medicine, Stanford University Course Director, Faculty Advisor-Imvaria|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lung Bioengineering Gerald J Berry, … disclose Tushar Jasubhai Desai, MD Professor Stanford Health Care (SHC) Faculty Grant or research support-Genentech, Inc.|Grant or research support-Boehringer Ingelheim Vetmedica GmbH (Relationship has ended)|Consulting Fee-YAP Therapeutics Christine K Garcia, MD, PhD Professor Columbia University Faculty Paid consultant-Rejuveron Telomere Therap
Participating Companies | Texas Life Science Forum Skip to main content BioHouston Rice Alliance Register Search Close Register Investors Sponsors Agenda Speakers Participating Companies Search Search Close Open Menu Close Register Investors Sponsors Agenda Speakers Participating Companies BioHouston Rice Alliance Register Enter a Search Term Search Participating Companies Congratulations to the 2025 Winners! See the winners and full list of participating companies below. Download Company Directory Congratulations to the Most Promising Companies and People's Choice winners from the 14th Annual … Choice: Roam Technologies Michael E. DeBakey Memorial Life Science Award, presented by BioHouston: IonTX Image Image Image 2025 Participating Companies 4M Therapeutics 7 Hills Pharma Acuamark Diagnostics Allterum Therapeutics Alwayslab Aspira Medical Bectas Therapeutics Cardiost Circurna CrossBridge Bio Dynamic Light ENB Therapeutics Endomedix Fixnip US Freyya HydroGene Therapeutics Indapta Therapeutics InterAct Therapeutics IonTX Iterion Therapeutic
Baylor College of Medicine’s Inaugural Biotechnology and Healthcare Innovation Forum - BCM Skip to content During the Lab-to-Life Match, every dollar you give will be matched! Donate Now ➔ Our Work Healthcare Education Research Community Lillie and Roy Cullen Tower President’s Strategic Initiatives Ways to Give Give Online Give Monthly Give in Honor or Memory Gift and Estate Planning Donate Stock More Options Get Involved The Partnership Events BRASS The Jaworski Society Corporate and Foundation Partners Grateful Patient Program DeBakey Society Family Council Your Impact Patient Stories